FDA announces September 14, 2026 public hearing on the potential future therapeutic use of psychedelic drugs

The U.S. Food and Drug Administration will hold a public hearing on September 14, 2026, to gather feedback on issues related to the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings. The hearing will take place from 12:30 p.m. to 4:30 p.m. Eastern Time, with attendance available online by webcast or in person at the FDA’s White Oak Campus in Silver Spring, Maryland. Requests to present are closed, but people may still register to attend and submit written comments. Written comments must be filed through the Federal Register electronic system by 11:59 p.m. ET on October 5, 2026. The event is held with federal partners and concerns regulatory and development considerations for psychedelic drug products.